Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?

Transfus Apher Sci. 2016 Feb;54(1):30-4. doi: 10.1016/j.transci.2016.01.009. Epub 2016 Jan 12.


There is some preliminary evidence, that veno-occlusive disease prophylaxis with defibrotide (DF) may also have a role in decreasing risk of acute graft-versus-host disease (aGvHD) by preventing tissue damage. In this study, we aimed to investigate the role of DF prophylaxis on the development of aGvHD at D+180. One hundred ninety-five consecutive adult patients receiving allogeneic HCT were retrospectively evaluated in 3 groups: no DF, DF/post-HCT (DF D+1 to D+14) and DF/pre-HCT (DF for 14 days concurrently with conditioning). The total (p: 0.057) and grades III/IV (p: 0.051) aGvHD rates at D+180 were 46.5%, 40%, 25.5% and 15.5%, 11.2%, 0% in patients on no DF, DF/post-HCT and DF/pre-HCT. DF may have a role in decreasing incidence and severity of aGvHD, especially if used concurrently with conditioning regimen.

Keywords: Acute GVHD; Acute graft-versus-host disease; Defibrotide; Prophylaxis.

MeSH terms

  • Adolescent
  • Adult
  • Blood Grouping and Crossmatching
  • Female
  • Graft vs Host Disease / drug therapy
  • Graft vs Host Disease / epidemiology
  • Graft vs Host Disease / etiology*
  • Graft vs Host Disease / prevention & control*
  • Hematopoietic Stem Cell Transplantation / adverse effects*
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Polydeoxyribonucleotides / therapeutic use*
  • Tissue Donors
  • Transplantation, Homologous / adverse effects
  • Young Adult


  • Polydeoxyribonucleotides
  • defibrotide